Overexpression of MYC transforms cells in culture, elicits malignant tumours in experimental animals and is found in many human tumours. We now report the paradoxical finding that this powerful oncogene can also act as a suppressor of cell motility, invasiveness and metastasis. Overexpression of MYC stimulated proliferation of breast cancer cells both in culture and in vivo as expected, but inhibited motility and invasiveness in culture, and lung and liver metastases in xenografted tumours. We show further that MYC represses transcription of both subunits of α v β 3 integrin, and that exogenous expression of β 3 integrin in human breast cancer cells that do not express this integrin rescues invasiveness and migration when MYC is downregulated. These data uncover an unexpected function of MYC, provide an explanation for the hitherto puzzling literature on the relationship between MYC and metastasis, and reveal a variable that could influence the development of therapies that target MYC.
The proto-oncogene MYC encodes an exceptionally pleiotropic transcription factor (MYC) that participates in the control of a wide variety of genes [1] [2] [3] . Included among these genes are functions vital to regulation of the cell cycle, cell growth, apoptosis, cell adhesion and genomic stability [3] [4] [5] . Overexpression of MYC transforms cells in culture 6 , elicits tumours in experimental animals 7 and is found in as many as 50% of all human cancers and 25% of human breast cancers [8] [9] [10] [11] [12] [13] . Paradoxically, such overexpression is on occasion dissociated from the propensity to invade and metastasize 10, [13] [14] [15] [16] [17] [18] . These observations raise the possibility that MYC may inhibit cellular properties such as motility and invasion that are essential to metastasis. Consistent with this possibility, overexpression of MYC in mouse skin causes a severe impairment in wound healing and in keratinocyte migration, whereas deletion of MYC causes increased migration of keratinocytes 19, 20 . Cellular invasion and migration are governed by extracellular and intracellular signals, and depend on the interaction of the cell with ligand molecules in the extracellular matrix [21] [22] [23] (ECM). The principal ECM receptors are the integrins, and altered expression of integrins is associated with tumour growth and metastasis 24, 25 . Overexpression of MYC was found to inhibit the spreading and adhesion of primary keratinocytes, which exhibited decreased expression of α 6 , β 1 and β 4 integrins in response to MYC expression 26 . When MYC was overexpressed in cells from neuroblastomas and sarcomas, the levels of α 3 and β 1 integrins were downmodulated 27, 28 , whereas genetic ablation of MYC in haematopoietic stem cells stimulated the expression of α 2 , α 5 and β 1 integrins, and other ECM proteins 29 . In addition, MYC binds to the E-box sequence of the promoters of the α 3 and α 7 integrin genes and silences their transcription in mouse myoblast and human sarcoma cells 27, 30 . We report here that elevated expression of MYC reduced the motility and invasiveness of breast cancer cells in vitro, their capacity for local invasion and their ability to seed distant metastases. Concomitantly, MYC overexpression inhibited the formation of stress fibres and focal adhesions. These effects of MYC could be attributed to the decreased expression of α v and β 3 integrins, mediated by repression of transcription from the corresponding genes. Our results provide an explanation for the dissociation between overexpression of MYC and metastasis, point to α v and β 3 integrins as crucial elements in the metastasis of malignant cells and uncover a variable that may be important in the development of therapeutics that target MYC.
RESULTS

MYC inhibits invasion and metastasis
We explored the role of MYC in metastasis by manipulating expression of the gene in four established cell lines of human breast cancer, two of which express little MYC (MDA-MB-231 and BD549) and two of which express MYC at high levels (MCF-7 and T47D; Fig. 1a) , and in human retinal pigment epithelium (RPE) cells, a cell line that has been used previously for investigating the effects of MYC on induction of proliferation and apoptosis. Exogenous overexpression of human MYC in MDA-MB-231, BT549 and RPE cells significantly increased proliferation assessed by BrdU labelling (Fig. 1b) without enhancing basal levels of cell death (Fig. 1c) . However, overexpression of MYC significantly inhibited migration of these cells (Fig. 1d ) and reduced invasiveness of MDA-MB-231 and BT549 cells (Fig. 1e) . Overexpression of MYC in MDA-MB-231 and BT549 cells also inhibited the invasive growth pattern of these cells when cultured in three-dimensional, laminin-rich gels (lrECM) such as Matrigel (Fig. 1f) . When injected subcutaneously, MYC-expressing MDA-MB-231 cells produced tumours that showed substantially reduced local invasion (Fig. 1g) , even though the expression of MYC led to significantly larger tumours (Fig. 1h) . These results showed that overexpression of MYC simultaneously promotes cell proliferation while inhibiting invasion, both in culture and in vivo.
Invasion and metastasis are both characteristics of cancer progression. We found that MDA-MB-231 cells overexpressing MYC showed significantly reduced incidence of lung metastases following injection into the tail vein (Fig. 2a,b) , although occasional MYC-expressing cells that did metastasize resulted in larger tumours (Fig. 2c) . To assess tumour growth and metastasis from the orthotopic site, MDA-MB-231-vector and MDA-MB-231-MYC cells were transduced with luciferase-expressing virus (Fig. 2d) and injected into the inguinal mammary gland. We found that the MYC-expressing tumours, as expected, grew more rapidly at the orthotopic site ( Fig. 2e-g ). However, isolation and quantification of luminescence of lungs (Fig. 2h,i) and livers (Fig. 2m,n) revealed decreased metastatic burden at 6 weeks following injection, although the difference was not statistically significant.
Metastatic burden is a combination of both number of metastases and the size of the metastatic tumours; we found that expression of MYC significantly reduced the number of metastases but led to increased size of individual metastases in both lung (Fig. 2j-l) and liver ( Fig. 2o-q) . We conclude that overexpression of MYC can stimulate cell proliferation, producing larger tumours that have reduced invasiveness and metastatic potential. These findings are consistent with recent indications that dissemination of tumour cells may occur early during tumour progression and is not necessarily linked to primary tumour size 31 .
MYC modulates cell interaction with the ECM
Motility is a dynamic process associated with major changes in cellular phenotype including spreading, actin polymerization, formation of actin-rich protrusions at the leading edge of migrating cells, and creation and dissolution of focal adhesions during cell translocation 32, 33 . We found that exogenous overexpression of MYC in both MDA-MB-231 and RPE cells (Fig. 3a,b ) reduced cell spreading, decreased stress fibre and focal adhesion formation, and increased cortical actin (Fig. 3c,d ). As formation of focal adhesions requires the interaction of cell surface integrins with their ligands in the ECM, we reasoned that the effect of overexpression of MYC on focal adhesion might reflect a defect in the interaction of cells with specific ECM ligands. To test this hypothesis, we assessed cell attachment to purified human ECM ligands and found that overexpression of MYC in MDA-MB-231 or RPE cells reduced their attachment to vitronectin (Fig. 3e,f) . Such defects could in turn impair cellular motility. To explore this possibility, we measured chemotaxis towards purified vitronectin in Boyden chamber assays, Results are expressed as mean ± s.e.m. * P < 0.05; * * * P < 0.005.
and found that overexpression of MYC in MDA-MB-231 and RPE cells decreased migration of both cell types (Fig. 3g,h ).
MYC inhibits expression of α v and β 3 integrins
To explore the mechanism by which MYC impedes invasion and motility, we measured the expression of subunits of α v β 3 integrin, which is a well-known cell surface receptor for vitronectin 34 . Overexpression of MYC in RPE, MDA-MB-231 and BT549 cells was accompanied by substantial reductions in both integrin subunits in all three cell lines, and less consistent reductions of α 5 , β 1 and β 5 subunits (Fig. 4a) . Conversely, when the high levels of endogenous MYC in MCF-7 and T47D cells were knocked down by short interfering RNA (siRNA), the levels of α v , α 5 , β 1 and β 5 integrin subunits rose ( Fig. 4a and data not shown). Irrespective of the level of MYC expression, β 3 integrin could not be detected by either PCR with reverse transcription or western blots in MCF-7 cells 35 ( Fig. 4a , and data not shown), nor in T47D cells (see below). Hence, both cell lines seem to be intrinsically deficient in β 3 .
Overexpression of MYC in MDA-MB-231 cells caused a reduction of RNA for both α v and β 3 (Fig. 4b,c) . A canonical E-box binding site for MYC is located upstream of the transcription initiation sites for both α v (CACATG) and β 3 (CACGTG) integrins in human DNA (Fig. 4d) . Quantitative chromatin immunoprecipitation (ChIP) assays showed that MYC bound directly to the E-box region of both these genes in MDA-MB-231 cells (Fig. 4e ,f) and in RPE cells (not shown), but not to nonspecific sequences in the same domain. Although MYC was originally viewed as a transcriptional activator, it can also serve as a transcriptional repressor 36 . Our results show that overexpression of MYC represses transcription of integrin genes involved in migration and metastasis.
Inhibition of invasion and metastasis by MYC depends on α v and β 3 integrin modulation
We found that the invasive and migratory phenotype of MDA-MB-231 and RPE cells was dependent on α v β 3 integrin (Fig. 5a,b , and data not shown), as was the invasive growth of MDA-MB-231 cells in lrECM (Fig. 5c) , and that defects in cell invasion and migration caused by overexpression of MYC could be partially or completely rescued by expressing α v and β 3 integrins in MDA-MB-231 ( Fig. 5d) , RPE (Fig. 5e ) or BT549 (Fig. 5f ) cells. Invasive growth of MDA-MB-231 in threedimensional (3D) lrECM and cell spreading, focal adhesion and stress fibre formation in RPE cells were rescued as well (Fig. 5g) . To evaluate whether exogenous overexpression of α v and β 3 integrins was sufficient to reconstitute metastatic capability in cells also overexpressing MYC, we generated MYC-expressing MDA-MB-231 cells that also expressed integrin α v and integrin β 3 using exogenous promoters unaffected by MYC (Fig. 5h ). When these cells were implanted orthotopically, ectopic expression of integrins α v and β 3 substantially increased lung metastasis (Fig. 5i,j) . These results indicate that suppression of integrin α v β 3 expression is the key mechanism by which MYC inhibits breast cancer cell metastasis. We noticed that depletion of either α v or β 3 integrin resulted in a parallel reduction of the other (Fig. 5a,b) ; conversely, exogenous expression of β 3 integrin increased the amount of α v integrin (see below, Fig. 6c ,e and Supplementary Figs S1 and S2). Moreover, exogenous expression of either integrin at least partially rescued the phenotype suppressed by MYC (Fig. 5d-g ). These findings could be explained by mass action, wherein an increase in either integrin alone can augment the formation of heterodimers and stabilize both components. We explored this possibility by co-immunoprecipitation to detect the formation of heterodimers. We found that transfection of α v and β 3 , either individually or together, substantially increased the amount of heterodimers in extracts of MDA-MB-231 cells (Supplementary Fig. S1 ). The relative amounts of heterodimer correlated with the extent to which exogenous expression of the integrins rescued a defect in invasion caused by MYC (compare Fig. 5d with Supplementary Fig. S1 ). We conclude that the defects in motility and invasion elicited by overexpression of MYC are due to reduced expression of the α v and β 3 integrin subunits, which in turn reduces formation of the heterodimer.
MYC prevents β 3 -integrin-induced cell invasion
We also explored the effect of depleting the high level of MYC in MCF-7 cells with RNA interference (Fig. 6a) . Depletion of MYC significantly reduced cellular proliferation as expected (data not shown), whereas it increased cell adhesion to vitronectin and fibronectin (Fig. 6b) , as well as cell spreading, focal adhesion and stress fibre formation (Fig. 6g) . However, knockdown of MYC in these cells neither increased cell motility (data not shown) nor invasiveness (Fig. 6j) , implicating the absence of β 3 integrin in MCF-7 cells and the consequent inability to form α v β 3 heterodimers. Accordingly, exogenous expression of β 3 integrin in MCF-7 cells (Fig. 6c,i) increased invasiveness (Fig. 6d,j) as well as cell spreading (Fig. 6h) ; similar effects were seen with exogenous expression of β 3 integrin in T47D cells (Fig. 6e,f and data not shown) .
MCF-7 cells grow in a cuboidal morphology with tight cell-cell junctions that restrict individual cell motility. To isolate the inhibitory effect of MYC on cell motility, we simultaneously knocked down E-cadherin and MYC, and expressed exogenous β 3 integrin in MCF-7 cells (Fig. 6i) . This combination greatly increased invasion (Fig. 6j) . We conclude that when cell-cell interactions are abrogated, inhibition of α v and β 3 -integrin expression is the primary barrier to cell 
DISCUSSION
MYC has been implicated extensively in tumour growth and cell transformation through studies in cultured cells 6, 37 , targeted expression in mice [38] [39] [40] and retrospective analyses of MYC expression in human tumours 8 . MYC is highly pleiotropic and plays multiple biological roles in driving tumorigenesis. Examples include the ability to initiate tumorigenesis in mice 7 , destabilization of the genome 4 and a requirement for maintenance of established tumours 41 . To this list we add here a previously unrecognized effect of MYC: the ability to inhibit metastasis through inhibition of transcription of an integrin involved in metastasis.
The possibility that MYC could act to inhibit metastasis could have been surmised by the observations that overexpression of the gene is sometimes dissociated from the tendency of tumours to metastasize 13, 15, 18 . Why this may be the case, however, had not been explored. In the case of human breast cancer, distal metastases may express MYC at the level of cognate normal cells, even though the gene is overexpressed in the primary tumour 13 . Similarly, mammary carcinoma and other tumours induced by MYC in mice frequently fail to metastasize. Examples include murine mammary cancer elicited by MYC under the control of the mouse mammary tumour virus promoter 15, 17 and aggressive breast tumours elicited by retroviral transduction of both MET and MYC into normal breast epithelial cells 18 . Here we explored the impact of MYC on metastasis by using cell lines derived from carcinomas of the human breast. Two of these lines express low levels of MYC and display a metastatic phenotype, whereas the other two overexpress the gene but do not metastasize. Irrespective of the reason for this variation, the differences in MYC expression allowed reciprocal studies on induction or repression of the metastatic phenotype by manipulation of MYC expression and its downstream targets. Clearly, human breast cancers that overexpress MYC may still metastasize if other factors override its function. In fact our in vivo assays demonstrated that expression of MYC will support increased growth of those few metastatic cells that escape the inhibitory function of MYC by means of other mutations or by changes in gene expression (Fig. 2m,r) .
Given this complexity, we sought direct experimental demonstration that MYC can indeed inhibit metastasis. Using MDA-MB-231 cells, the human cell line that expresses only low levels of MYC and is used extensively for metastatic studies, we confirmed their highly metastatic potential, by both tail vein injection (Fig. 2c,d ) and orthotopic implantation (Fig. 2i-r ) in mouse models. However, when exogenous MYC was overexpressed in these cells, their ability to metastasize was greatly reduced. Furthermore, the behaviour of breast cancer cell lines was remarkably malleable when the level of MYC was modulated: it was possible to reduce the metastatic properties by overexpressing MYC, or to augment those properties by reducing MYC levels. At the same time, MYC could increase proliferation even in overtly malignant cells (Fig. 1b) . We reported previously an apparent dichotomy between stimulation of proliferation and inhibition of other malignant properties of breast cancer cells also for the oncogene AKT1 (protein kinase B1; refs [42] [43] [44] .
Our finding that MYC overexpression leads to inhibition of cell motility and invasiveness through direct downmodulation of α v and β 3 integrin subunits supports reports that integrins with these subunits are involved in cellular motility, invasiveness, adhesion and transmigration through endothelium, and are associated with metastasis 22, 24, 35, 45, 46 . There are also reports that MYC may be involved in controlling the expression of integrin genes using cells from different tissues 26, 28, 29 . However, none of these reports has linked the effect of MYC on integrin expression to cellular components of metastasis, and none has implicated the α v β 3 heterodimer directly in the cellular changes elicited by MYC. Our results demonstrate that overexpression of MYC represses transcription from the promoters of the α v and β 3 integrin genes, which in turn reduces properties that are essential for metastasis. These data, however, do not mean that MYC affects invasion and metastasis only through regulation of integrins α v and β 3 , nor that MYC is the only regulator of integrin α v β 3 function in invasion and metastasis. The fact that MYC siRNA increases invasion when MCF-7 cells are forced to have high levels of integrins α v and β 3 (Fig. 6j) indicates that there may be mechanism(s) other than integrin α v β 3 by which MYC can inhibit invasion and metastasis. Nevertheless, as exogenous expression of these integrins is sufficient to bypass the repressive effect of MYC in invasion (Fig. 6d,f,j) and metastasis (Fig. 5h,j) , it is apparent that a primary effect of MYC on invasion in breast cancer cells is mediated through its inhibition of integrins α v and β 3 .
Tumour progression often culminates in metastatic disease, indicating that there must be selection for antidotes to the MYC inhibition of the metastatic phenotype. One obvious possibility would be selection against overexpression of MYC during the course of tumour progression. Indeed, the two breast cancer cell lines used in the present study that express relatively low levels of MYC both originated from metastatic tumours: MDA-MB-231 from pleural effusion and BT549 from an invasive ductal tumour in regional lymph nodes. Other possibilities include loss of β 3 integrin functions, as in the case of MCF-7 and T47D cell lines. Constitutive signalling from active Ras or overexpression of Bcl-XL can also override the inhibition of metastasis by MYC (unpublished results of H.L and D.Y). These complexities might account for the fact that in some experimental circumstances, MYC may seem to favour metastasis [47] [48] [49] . The findings reported here prompt a cautionary note about therapeutic strategies involving MYC. The frequency with which MYC is overexpressed, and the variety of tumours in which that overexpression occurs, have made MYC a seemingly advantageous therapeutic target 50 . Our findings raise the possibility that inhibition of MYC in human tumours might at times be contraindicated because its suppression may indeed promote metastasis.
METHODS
Methods and any associated references are available in the online version of the paper at www.nature.com/naturecellbiology Cells grown as a monolayer to 80% confluence were trypsinized as single cells and plated on top of Matrigel-coated dishes. After incubation at 37 • C for ∼20 min to allow the cells to settle down on top of the gel, medium was replaced with complete growth medium containing 5% Matrigel. Cells were cultivated for 6-8 days and medium was changed with fresh medium containing Matrigel every two days. Phase-contrast micrographs of representative fields were taken (Zeiss Axiovert25; Leica DFC420C, Leica Microsystems).
Immunoblot analysis. Cells were lysed in lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, at pH 7.4, 1 mM EDTA, 1 mM EGTA, containing 2 mM NaF, 1 mM sodium orthovanadate, 10 µg ml −1 leupeptin, 10 µg ml −1 pepstatin, 10 µg ml −1 aprotinin, 10 µg ml −1 E 64 and 1 mM Pefabloc; EMD). Equal amounts of protein lysates were loaded and separated by SDS-PAGE and followed by western blotting.
Immunofluorescence analysis and immunohistochemistry. Cells were fixed in 4% formaldehyde at room temperature for 10 min. The samples were blocked with blocking buffer (PBS, 1% BSA and, 0.2% Triton X-100) and then incubated with primary antibodies followed directly by either FITC or Texas Red-conjugated secondary antibodies for 45 min. Nuclei were counterstained with 4 , 6-diamidino-2-phenylindole (DAPI, Sigma). Immunohistochemistry was performed according to the standard protocol, using 1:400 dilution of primary antibody. The images were collected with a Zeiss 410 LSM confocal microscope (Zeiss Pluar 40 oil objective lenses) or a RT SLIDER SPOT digital camera (software: SPOT RT v3.2) attached to a Zeiss Photomicroscope III (Zeiss Plan-Neofluar 40 • C-oil objective lenses, Zeiss).
Adhesion assay. Plates (96-well) were coated with 50 µl per well of purified matrix proteins (10 µg ml −1 ) overnight at 4 • C. The plates were washed with PBS and blocked with 2% BSA in PBS for 2 h at 37 • C. Cells were washed with PBS, detached with 20 mM EDTA in PBS at 37 • C and dispersed as single cells. Cells were then washed three times with basic medium without FBS and suspended in the same medium at a concentration of 2×10 5 cells ml −1 . Cell suspension (100 µl) was added into each well with a multi-channel pipetteman. The plates were briefly centrifuged and incubated for 30-60 min at 37 • C. The unattached cells were removed by quickly decanting the plates and washing three times with PBS. The attached cells were fixed with 4% formaldehyde and stained with 0.5% crystal violet. Each condition was quadruplicated and attached cells were counted in five fields under ×400 magnification. The experiments were repeated at least twice. Invasion and migration assays. For the invasion assay, cell culture inserts (8 µm, 24-well format, Becton Dickinson Labware) were evenly coated with diluted Matrigel (1:5 dilution with blank medium). Cells (1 × 10 5 ) were added to the upper chamber and the lower chamber was filled with 300 µl medium containing 10% FBS. The culture was maintained for 24 h for MDA-MB-231 and BT549 cells, and 48 h for MCF-7 and T47D cells. The cell migration assay was similar to the invasion assay, except that inserts were not coated with Matrigel and the culture was maintained for 24 h. For the assay of cell migration on purified matrix proteins, cell culture inserts (8 µm, 24-well format, Becton Dickinson Labware) were first coated with the indicated matrix proteins in PBS (10 µg ml −1 ) at 4 • C overnight and then blocked with 2% BSA in PBS at 37 • C for 2 h. Cells (1 × 10 5 ) in serum-free medium were added to the upper chamber and the lower chamber was filled with 300 µl of the same medium. The culture was maintained for 3 h. Cells were then fixed with 4% formaldehyde for 10 min and stained with 0.5% crystal violet for 10 min. The cells on the upper side of the filters were removed with cotton-tipped swabs. The cells on the underside of the filters were counted under a ×20 objective lens in five randomly chosen fields. The results are presented as the fold change when compared with vector control cells.
Metastasis assays.
Female nude mice (Foxn1-nu), 6-7 weeks of age, were purchased from Harlan. MDA-MB-231 cells expressing MYC or vector alone were propagated as monolayers and trypsinized. For tail inoculation, cells were resuspended in DMEM at a concentration of 2 × 10 6 cells ml −1 . Cell suspension (0.1 ml; 2 × 10 5 cells) was injected into tail veins of nude mice. All of the mice were killed by CO 2 , 6 weeks after inoculation. The lungs were removed, fixed in 4% formaldehyde, paraffin-embedded and sectioned (5 µm). Serial sections were stained with anti-human vimentin and all the nodules on both lungs were counted using ×5 objective lens. For subcutaneous inoculation, cells were resuspended in DMEM medium with 50% Matrigel at a concentration of 5 × 10 7 cells ml −1 . Cells (0.1 ml; 5×10 6 ) were injected into the right flank of female nude mice. The tumours were measured weekly and the tumour volume was calculated according to the formula length × width 2 /2. The mice were killed 4 weeks after the inoculation. For orthotopic metastasis assays, cells were transduced with pSin-Luc and 1 × 10 6 cells were mixed with growth-factor-reduced Matrigel and injected into the inguinal mammary gland in 7-week-old NOD/SCID mice. For weekly imaging, mice 
